Boosh Settles $190,000 In Debt

Boosh Settles $190,000 In Debt

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") announces that it has entered into a settlement agreement with an arm's length third party for the settlement of $191,428.52 in debt for services previously provided through the issuance of 1,519,274 common shares at a deemed price of $$0.126 per share.

All securities issued in the debt settlement are subject to a four month and one day hold period expiring on December 04, 2022.

Boosh Plant-Based Brands continues its strong sales trajectory across Canada and the US with its premiere brand of better for you chips Beanfields, Boosh ready to eat meals and Amuse boosh vegan cheese and pate.

On behalf of the Board of Directors

Connie Marples
Founder/Chief Executive Officer
connie@booshfood.com

Telephone: (778) 840 1700

www.Booshfood.com

About Boosh Plant-Based Brands Inc.:

Boosh Plant-Based Brands Inc., through its wholly owned subsidiary, Boosh Food (www.booshfood.com), offers high quality, non-GMO, gluten free, 100% plant-based nutritional comfort foods for the whole family. Through a separate subsidiary, Beautiful Beanfields, the Company owns Beanfields, a plant-based chips brand sold in over 7,000 stores throughout North America. Boosh, good for you and good for planet earth.

The information in this news release includes certain information and statements about management's view of future events, expectations, plans and prospects that constitute forward looking statements. These statements are based upon assumptions that are subject to significant risks and uncertainties. Because of these risks and uncertainties and as a result of a variety of factors, the actual results, expectations, achievements or performance may differ materially from those anticipated and indicated by these forward-looking statements. Forward-looking statements in this news release include, but are not limited to, the Company's expectations for additional financing, its plan for the proceeds of the placement. Any number of factors could cause actual results to differ materially from these forward-looking statements as well as future results. Although the Company believes that the expectations reflected in forward looking statements are reasonable, it can give no assurances that the expectations of any forward-looking statements will prove to be correct. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward -looking statements to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward looking statements or otherwise.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/133023

News Provided by Newsfile via QuoteMedia

VEGI:CC
The Conversation (0)
Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Hires Pixie Brands and Multi Brands Sampling Co for BC Promos and Store Sampling

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, announced today it is working with Pixie Brands @meetpixiebrands and Multi Brand Sampling Co @multibrandsmaplingco to promote and enhance sales at store level for all Boosh and Beanfields brands in BC.

Founded by CPG founder April Angelini, Pixie Brands offers a relationship-based, boots on the ground approach to help small and medium brands SHINE. They offer sales and distributor support and organize In-Store Events.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Expands into United Sates Hospitality Services Sector

Boosh Expands into United Sates Hospitality Services Sector

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector announced today it has begun production of 1.5 oz bags of Beanfields Chips to open up sales to the US hospitality sector. Beanfields Snacks, the primary asset of Boosh Plant Based Brands, represents a significant growth opportunity in the salty snacks sector.

Prior to Boosh Plant-Based Brands acquiring the asset Beanfields Chips, the previous owners had made inroads into the hospitality sector with accounts at Universities, Corporate offices and numerous independent quick serve and convenience stores representing annual sales of $1.7M CAN.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Announces Shares for Debt Transaction

Boosh Announces Shares for Debt Transaction

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company") a premier plant-based brand in the "better for you" food sector announced today that it had entered into, and that it had finalized a secondary set of debt settlement agreements with the purpose to both satisfy and to extinguish an aggregate total of C$722,710 of secured debts. A combined total of 16,060,207 common shares were issued at a deemed price of C$0.045 per common share.

The Company decided to satisfy the indebtedness with common shares to preserve its cash for the development of its business. No new control person of the Company will be created pursuant to the settlement of the debt settlement agreements.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement

Boosh Plant-Based Brands Inc. Announces Engagement with Storied Health Partners and Debt Settlement

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77i) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, is pleased to announce that it has engaged Storied Health Partners, a resource-rich platform that provides entrepreneurs the support and leverage they need to maximize their growth potential and accomplish their brand's next milestone.

CEO of Storied Health Partners, Anis Barakat, is a food and beverage expert with nearly a decade of experience in senior leadership roles in the industry. Mr. Barakat is the founder and former President of Revive Superfoods, the first multi-national frozen superfood subscription company selling ready-to-eat/blend meals such as smoothies, oats, soups and lunch/dinner bowls direct-to-consumer throughout the United States, Canada and UAE. During his time with Revive Superfoods, Anis was instrumental in developing a highly scalable direct-to-consumer ("DTC") subscription model that disrupted the ready-meal industry and achieved incredible success since its inception in 2018.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023

CORRECTION FROM SOURCE: Correction of the Press Releases Dated January 9, 2023 and March 14, 2023

Boosh Plant-Based Brands Inc. (CSE: VEGI) (OTCQB: VGGIF) (FSE: 77I) ("Boosh" or the "Company"), a premier plant-based brand in the "better for you" food sector, issues the following corrected press release to the press releases dated January 9, 2023 and March 14, 2023 concerning the completion of a non-brokered private placement for gross proceeds of $362,000.

The corrections are being made to correct and restate the terms of the previously announced non-brokered private placement.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Row of test tubes and pipette with chemical droplet chemical coming from it.

Top 5 NASDAQ Biotech Stocks

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) has traded at three-year highs in the first half of 2024 in response to looming interest rate cuts, breakthrough innovations and increased deals in the space.

After dropping to a low of 3,637.05 in October 2023, the index climbed to start 2024 at 4,457.02. It did hit a bump in the road early in Q2 when it plunged to 4,056.3 in April, but it quickly recovered and has since tracked even higher, reaching 4,634.21 on June 24. But while the current economic environment means the biotech sector may have a complex road ahead, robust growth could be in store in the future.

According to a recent report from Precedence Research, the global biotech market is expected to grow at a compound annual growth rate of 11.8 percent from now to 2033, reaching a valuation of US$4.25 trillion.

Keep reading...Show less
Radiopharm Theranostics

First Patient Dosed with PD-L1 Nanobody in Phase 1 Therapeutic Non-Small Cell Lung Cancer Trial

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the therapeutic dosing of the first patient in its Phase 1 clinical trial of RAD 204, a proprietary nanobody which targets Programmed death-ligand 1 (PD-L1)-positive expression in Non-Small Cell Lung Cancer (NSCLC), the most common type of lung cancer.

Keep reading...Show less
Test tubes.

Can AI Help Detect Cancer? Data Analysis Could Open Up Possibilities for Healthcare Industry

Artificial intelligence (AI) has emerged as a valuable tool for solving complex societal issues, and although it's a new industry, its impact is already being felt in key areas of the life science sector.

AI models in healthcare are quickly advancing beyond basic tasks like medical transcription and administrative streamlining; many systems can now effectively analyze extensive genetic data.

By harnessing AI models' ability to identify patterns and make predictions, medical professionals can institute more effective, personalized treatments and develop precision tests to catch diseases earlier.

Keep reading...Show less
Biotech therapy capsule containing DNA strand surrounded by cells.

Top 3 Canadian Biotech Stocks of 2024

Biotech is a dynamic industry that is driving scientific advancements and innovation in healthcare.

According to Grandview Research, the global biotech market was worth US$1.55 trillion in 2023, and the firm expects it to grow at a CAGR of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.

In Canada, the biotech industry is home to companies pursuing cutting-edge therapies and medical technologies, and the Investing News Network has identified the top three biotech stocks based on their year-on-year gains.

Keep reading...Show less
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less

Latest Press Releases

Related News

×